Cellebrite DI (NASDAQ:CLBT - Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $107.26 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. The business had revenue of $106.90 million for the quarter, compared to analysts' expectations of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business's quarterly revenue was up 27.0% on a year-over-year basis. During the same period last year, the business earned $0.09 earnings per share. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cellebrite DI Trading Up 0.8 %
Shares of CLBT traded up $0.20 during mid-day trading on Friday, reaching $25.41. The company's stock had a trading volume of 2,173,997 shares, compared to its average volume of 1,762,856. Cellebrite DI has a 52 week low of $8.91 and a 52 week high of $26.30. The company's fifty day moving average price is $22.31 and its two-hundred day moving average price is $18.85. The stock has a market cap of $5.23 billion, a PE ratio of -16.39, a P/E/G ratio of 3.72 and a beta of 1.47.
Analysts Set New Price Targets
Several analysts have issued reports on CLBT shares. Craig Hallum upped their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Monday, December 16th. Finally, Needham & Company LLC raised their price target on Cellebrite DI from $21.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, January 22nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $21.57.
Get Our Latest Stock Analysis on Cellebrite DI
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
